A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

NCT01929317 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Ropinirole CR 2mg tablet
DRUG: Ropinirole CR 8mg tablet
DRUG: Ropinirole CR matching Placebo tablet

Sponsor

GlaxoSmithKline